Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

verubecestat

- PMLiVE

AZ, Merck’s Lynparza scores market-expanding clinical success

Positive phase 3 findings in ovarian cancer

- PMLiVE

Keytruda scores in neoadjuvant triple negative breast cancer combo

Tecentriq still in pole position

- PMLiVE

Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms

Latest BACE inhibitor to run into trouble

- PMLiVE

Pharma fears “lack of focus” on no-deal Brexit preparations

As Brexit is delayed, pharma suggests new measures to avoid no-deal drugs shortages

- PMLiVE

Undeterred by aducanumab failure, Eisai and Biogen plough on

Investors sceptical, though mechanism different

- PMLiVE

Where next in Alzheimer’s disease R&D?

How past failures and emerging biology are reshaping drug development

- PMLiVE

Biogen and Eisai pull plug on Alzheimer’s drug

Further undermines amyloid-targeting approach

Brain power: fresh approaches to Alzheimer’s drug discovery

New alliances are learning from past mistakes and breaking down research barriers

- PMLiVE

Greater Manchester backs move to outcome-based payment

Region teams up with Cancer Research UK to accelerate change

- PMLiVE

GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn

Partners to co-develop novel bifunctional fusion protein

- PMLiVE

Lilly partners with AC Immune on tau drug for Alzheimer’s

Potential payments of $1.7bn to Swiss firm

- PMLiVE

Tackling a formidable foe

Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links